BioSpace News Archive

Adaptive Biotechnologies Corporation announced new data demonstrating the expanding use of Adaptive’s next-generation sequencing -based clonoSEQ® test in assessing minimal residual disease in blood cancer patient care and in clinical trials.

Genentech, a member of the Roche Group, announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors.

X4 Pharmaceuticals announced the presentation of additional preliminary data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without concurrent treatment with injectable granulocyte-colony stimulating factor in people diagnosed with idiopathic, cyclic, or congenital neutropenia.

Galapagos NV topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia, with or without Richter transformation, and non-Hodgkin lymphoma, during two poster sessions at the 65th ASH Annual Meeting taking place in San Diego, from 9-12 December.

AbbVie and Genmab A/S announced that adult patients with relapsed/refractory follicular lymphoma previously treated with two or more prior therapies experienced strong and durable responses with high overall response and complete response rates when treated with epcoritamab, an investigational, subcutaneously administered T-cell engaging bispecific antibody.

Genmab A/S and AbbVie announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate of 82 percent, a complete response rate of 63 percent and minimal residual disease negativity rate of 67 percent in patients with relapsed/refractory follicular lymphoma.

The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that remove germs.

FibroGen, Inc. announced the presentation of efficacy and safety data from MATTERHORN, a Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes at the 65th American Society of Hematology Annual Meeting and Exposition being held in San Diego, California December 9 - 12, 2023.

Biomea Fusion, Inc. announced top line data of the 200 mg dose cohorts from the ongoing Phase II clinical study which will be presented in more detail at the International Conference on Advanced Technologies and Treatments of Diabetes in March 2024.

Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute myeloid leukemia at the 65th American Society of Hematology Annual Meeting and Exposition.